A panel of independent medical experts voted 17-4 in favor of food and drug administration on Thursday, giving BioNTech and Pfizer Inc. emergency approval for the COVID-19 vaccine candidate. Shares of Bioendech PNTX, + 5.48%, rose 1.8%, while Pfizer’s PFE, -0.29%, rose 1.8% after trading on Thursday. The ball is now in FDA court. Vaccines and related biological products do not require the regulator to follow the recommendation of the members of the advisory board, but often do so. Federal officials said they expect the regulator to make a decision on the vaccine in a few days. The Bioentech and Pfizer vaccine is already approved in Bahrain, Canada and the United Kingdom. During a one-day meeting held at a distance on Thursday, medical experts, FDA officials, Pfizer executives and members of the public discussed the risks and benefits of the tested Govt-19 vaccine. At the end of the day, the team voted on a question: Based on the available scientific evidence, are the benefits of the Pfizer-Bioentech Covit-19 vaccine greater than the risks of use for individuals 16 years of age or older? (Seventeen members voted ‘yes’ to this question, four voted ‘no’, and one voted.) Some of the key issues discussed during the meeting included: Vaccine for 16- and 17-year-olds to use to see if there is adequate authorization to use from stage 3 medicine. (Companies are looking for a reference to allowing teens under this age to be vaccinated.) Some patients, such as pregnant women and those living with HIV / AIDS, have to respond to reports of allergic reactions to two people who were vaccinated by the FDA in the UK this week. (No allergic reactions were reported during the clinical trial, Pfizer told the board.) So far this year, Pfizer’s shares have risen 13.1%, while Bioendech’s have risen 269.3%. The S&P 500 SPX is up -0.13%, up 13.7% from the beginning of this year. .
Source